<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35202463</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>03</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1598</StartPage><EndPage>1609</EndPage><MedlinePgn>1598-1609</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awac077</ELocationID><Abstract><AbstractText>Frontotemporal dementia refers to a group of neurodegenerative disorders characterized by behaviour and language alterations and focal brain atrophy. Amyotrophic lateral sclerosis is a rapidly progressing neurodegenerative disease characterized by loss of motor neurons resulting in muscle wasting and paralysis. Frontotemporal dementia and amyotrophic lateral sclerosis are considered to exist on a disease spectrum given substantial overlap of genetic and molecular signatures. The predominant genetic abnormality in both frontotemporal dementia and amyotrophic lateral sclerosis is an expanded hexanucleotide repeat sequence in the C9orf72 gene. In terms of brain pathology, abnormal aggregates of TAR-DNA-binding protein-43 are predominantly present in frontotemporal dementia and amyotrophic lateral sclerosis patients. Currently, sensitive and specific diagnostic and disease surveillance biomarkers are lacking for both diseases. This has impeded the capacity to monitor disease progression during life and the development of targeted drug therapies for the two diseases. The purpose of this review is to examine the status of current biofluid biomarker discovery and development in frontotemporal dementia and amyotrophic lateral sclerosis. The major pathogenic proteins implicated in different frontotemporal dementia and amyotrophic lateral sclerosis molecular subtypes and proteins associated with neurodegeneration and the immune system will be discussed. Furthermore, the use of mass spectrometry-based proteomics as an emerging tool to identify new biomarkers in frontotemporal dementia and amyotrophic lateral sclerosis will be summarized.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katzeff</LastName><ForeName>Jared S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bright</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Centre, Macquarie Medical School, Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phan</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kril</LastName><ForeName>Jillian J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Centre, Macquarie Medical School, Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ittner</LastName><ForeName>Lars M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0001-6738-3825</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Macquarie Medical School, Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kassiou</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodges</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piguet</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Psychology, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda M</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0003-0422-8398</Identifier><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Woojin Scott</ForeName><Initials>WS</Initials><Identifier Source="ORCID">0000-0002-4707-933X</Identifier><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020774" MajorTopicYN="Y">Pick Disease of the Brain</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">neurofilament</Keyword><Keyword MajorTopicYN="N">proteomics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>17</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35202463</ArticleId><ArticleId IdType="pmc">PMC9166557</ArticleId><ArticleId IdType="doi">10.1093/brain/awac077</ArticleId><ArticleId IdType="pii">6535863</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386(10004):1672&#x2013;1682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5970949</ArticleId><ArticleId IdType="pubmed">26595641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MA, Bickel H, Prince M, et al. . Estimating the burden of early onset dementia; systematic review of disease prevalence. Eur J Neurol. 2014;21(4):563&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">24418291</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney NT, Spina S, Miller BL. Frontotemporal dementia. Neurol Clin. 2017;35(2):339&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5472209</ArticleId><ArticleId IdType="pubmed">28410663</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Ravenscroft TA, Sanchez-Contreras M, Rademakers R. Genetics of FTLD: Overview and what else we can expect from genetic studies. J Neurochem. 2016;138(Suppl 1):32&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">27009575</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter ML, Pawelke S, Bisenius S, et al. . A modified reading the mind in the eyes test predicts behavioral variant frontotemporal dementia better than executive function tests. Front Aging Neurosci. 2018;10:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5797534</ArticleId><ArticleId IdType="pubmed">29441012</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall CR, Hardy CJD, Volkmer A, et al. . Primary progressive aphasia: A clinical approach. J Neurol. 2018;265(6):1474&#x2013;1490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990560</ArticleId><ArticleId IdType="pubmed">29392464</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollacott IO, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. J Neurochem. 2016;138(Suppl 1):6&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">27144467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciervo Y, Ning K, Jun X, Shaw PJ, Mead RJ. Advances, challenges and future directions for stem cell therapy in amyotrophic lateral sclerosis. Mol Neurodegener. 2017;12(1):85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5683324</ArticleId><ArticleId IdType="pubmed">29132389</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: From genes to mechanism. Nature. 2016;539(7628):197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol. 2016;138:225&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. . Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084&#x2013;2098.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. . Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR. Motor neuron disease: Biomarker development for an expanding cerebral syndrome. Clin Med (Lond). 2016;16(Suppl 6):s60&#x2013;s65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6329564</ArticleId><ArticleId IdType="pubmed">27956443</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Ciura S, Rouleau GA, Kabashi E. Defining the genetic connection linking amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD). Trends Genet. 2015;31(5):263&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">25869998</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LH, Kaat LD, Rohrer JD, van Swieten JC. Imaging and fluid biomarkers in frontotemporal dementia. Nat Rev Neurol. 2017;13(7):406&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">28621768</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Ke YD, Ittner LM, Halliday GM. ALS/FTLD: Experimental models and reality. Acta Neuropathol. 2017;133(2):177&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">28058507</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. . Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 20 2011;72(2):257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Archetti S, Del Bo R, et al. . TARDBP mutations in frontotemporal lobar degeneration: Frequency, clinical features, and disease course. Rejuvenation Res. 2010;13(5):509&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">20645878</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9(10):995&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci. 2008;13:867&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">17981595</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. TDP-43: Gumming up neurons through protein-protein and protein-RNA interactions. Trends Biochem Sci. 2012;37(6):237&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">22534659</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Calvet M, Dols-Icardo O, Llado A, et al. . Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. J Neurol Neurosurg Psychiatry. 2014;85(6):684&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">24309270</ArticleId></ArticleIdList></Reference><Reference><Citation>Junttila A, Kuvaja M, Hartikainen P, et al. . Cerebrospinal fluid TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis patients with and without the C9ORF72 hexanucleotide expansion. Dement Geriatr Cogn Dis Extra. 2016;6(1):142&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4868946</ArticleId><ArticleId IdType="pubmed">27195002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai T, Tokuda T, Ishigami N, et al. . Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2009;117(1):55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">18989684</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder V, Gregory JM, Barria MA, Green A, Pal S. TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: A systematic review and meta-analysis. BMC Neurol. 2018;18(1):90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027783</ArticleId><ArticleId IdType="pubmed">29954341</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-based biomarker for ALS and FTLD. Mol Neurobiol. 2018;55(10):7789&#x2013;7801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132775</ArticleId><ArticleId IdType="pubmed">29460270</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Steinacker P, Lehnert S, et al. . Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5-6):351&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">24834468</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Tau filaments in neurodegenerative diseases. FEBS Lett. 2018;592(14):2383&#x2013;2391.</Citation><ArticleIdList><ArticleId IdType="pubmed">29790176</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirokawa N. Microtubule organization and dynamics dependent on microtubule-associated proteins. Curr Opin Cell Biol. 1994;6(1):74&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">8167029</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Bird TD, Wijsman E, et al. . Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43(6):815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, et al. . Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393(6686):702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J, Van Broeckhoven C. Dementia in 2013: Frontotemporal lobar degeneration&#x2014;building on breakthroughs. Nat Rev Neurol. 2014;10(2):70&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">24394289</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Benussi A, Archetti S, et al. . Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(1&#x2013;2):86&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">25352065</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Watts K, Grossman M, et al. . Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology. 2013;81(22):1945&#x2013;1952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843382</ArticleId><ArticleId IdType="pubmed">24174584</ArticleId></ArticleIdList></Reference><Reference><Citation>Foiani MS, Woollacott IO, Heller C, et al. . Plasma tau is increased in frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2018;89(8):804&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204947</ArticleId><ArticleId IdType="pubmed">29440230</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Trojanowski JQ, Grossman M. Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. Front Aging Neurosci. 2013;5:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578350</ArticleId><ArticleId IdType="pubmed">23440936</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, et al. . Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A, Karikari TK, Ashton N, et al. . Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2020;91(9):960&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">32611664</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman M, Elman L, McCluskey L, et al. . Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol. 2014;71(4):442&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989393</ArticleId><ArticleId IdType="pubmed">24492862</ArticleId></ArticleIdList></Reference><Reference><Citation>Foiani MS, Cicognola C, Ermann N, et al. . Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: An elusive quest. J Neurol Neurosurg Psychiatry. 2019;90:740&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6585261</ArticleId><ArticleId IdType="pubmed">30981993</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Halliday GM, Kril JJ, et al. . The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016;388(10047):919&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">26987909</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho WY, Tai YK, Chang JC, et al. . The ALS-FTD-linked gene product, C9orf72, regulates neuronal morphogenesis via autophagy. Autophagy. 2019;15(5):827&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6526867</ArticleId><ArticleId IdType="pubmed">30669939</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasio A, Decman V, White D, et al. . C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci Rep. 2016;6:23204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793236</ArticleId><ArticleId IdType="pubmed">26979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Suzuki N, Wang JY, et al. . Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med. 2016;8(347):347ra93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Yanez A, et al. . C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351(6279):1324&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, van Blitterswijk M, Zhang M, et al. . Jump from pre-mutation to pathologic expansion in C9orf72. Am J Hum Genet. 2015;96(6):962&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457950</ArticleId><ArticleId IdType="pubmed">26004200</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Zhang M, Bruni AC, et al. . The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta Neuropathologica. 2015;129(5):715&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">25716178</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lin S, Staats KA, et al. . Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med. 2018;24(3):313&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao FB, Almeida S, Lopez-Gonzalez R. Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. EMBO J. 2017;36(20):2931&#x2013;2950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641681</ArticleId><ArticleId IdType="pubmed">28916614</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V, Hasan GM, Hassan MI. Unraveling the role of RNA mediated toxicity of C9orf72 repeats in C9-FTD/ALS. Front Neurosci. 2017;11:711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736982</ArticleId><ArticleId IdType="pubmed">29326544</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekura K, Yagi T, Cammack AJ, et al. . Poly-dipeptides encoded by the C9ORF72 repeats block global protein translation. Hum Mol Genet. 2016;25(9):1803&#x2013;1813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986334</ArticleId><ArticleId IdType="pubmed">26931465</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Chew J, Stankowski JN, et al. . Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med. 2017;9(383):eaai7866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LHH, Gendron TF, Sias AC, et al. . Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann Clin Transl Neurol. 2018;5(5):583&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5945959</ArticleId><ArticleId IdType="pubmed">29761121</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmer C, Oeckl P, Weishaupt JH, et al. . Poly-GP in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD. EMBO Mol Med. 2017;9(7):859&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494528</ArticleId><ArticleId IdType="pubmed">28408402</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunton-Stasyshyn RK, Saccon RA, Fratta P, Fisher EM. SOD1 function and its implications for amyotrophic lateral sclerosis pathology: New and renascent themes. Neuroscientist. 2015;21(5):519&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">25492944</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, et al. . Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Saccon RA, Bunton-Stasyshyn RK, Fisher EM, Fratta P. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain. 2013;136(Pt 8):2342&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722346</ArticleId><ArticleId IdType="pubmed">23687121</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterstrom P, Andersen PM, Brannstrom T, Marklund SL. Misfolded superoxide dismutase-1 in CSF from amyotrophic lateral sclerosis patients. J Neurochem. 2011;117(1):91&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">21226712</ArticleId></ArticleIdList></Reference><Reference><Citation>Winer L, Srinivasan D, Chun S, et al. . SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013;70(2):201&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812918</ArticleId><ArticleId IdType="pubmed">23147550</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. . Phase 1&#x2013;2 trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A, Rao MV, Veeranna, Nixon RA. Neurofilaments at a glance. J Cell Sci. 2012;125(Pt 14):3257&#x2013;3263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516374</ArticleId><ArticleId IdType="pubmed">22956720</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, et al. . Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Cajanus A, Katisko K, Kontkanen A, et al. . Serum neurofilament light chain in FTLD: Association with C9orf72, clinical phenotype, and prognosis. Ann Clin Transl Neurol. 2020;7(6):903&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7318100</ArticleId><ArticleId IdType="pubmed">32441885</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL, Meeter LH, Poos JM, et al. . Serum neurofilament light chain in genetic frontotemporal dementia: A longitudinal, multicentre cohort study. Lancet Neurol. 2019;18(12):1103&#x2013;1111.</Citation><ArticleIdList><ArticleId IdType="pubmed">31701893</ArticleId></ArticleIdList></Reference><Reference><Citation>Panman JL, Venkatraghavan V, van der Ende EL, et al. . Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2021;92:494&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8053353</ArticleId><ArticleId IdType="pubmed">33452053</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas JC, Wang P, Staffaroni AM, et al. . Plasma neurofilament light for prediction of disease progression in familial frontotemporal lobar degeneration. Neurology. 2021;96:e2296&#x2013;e2312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8166434</ArticleId><ArticleId IdType="pubmed">33827960</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C, Preische O, Deuschle C, et al. . Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. J Neurol Neurosurg Psychiatry. 2016;87(11):1270&#x2013;1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">27188986</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LHH, Vijverberg EG, Del Campo M, et al. . Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology. 2018;90(14):e1231&#x2013;e1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5890612</ArticleId><ArticleId IdType="pubmed">29514947</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S, Mometto N, Bartoletti-Stella A, et al. . Cerebrospinal fluid biomarkers in patients with frontotemporal dementia spectrum: A single-center study. J Alzheimers Dis. 2018;66(2):551&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">30320576</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S, Vacchiano V, Zenesini C, et al. . Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J Neurol. 2020;267:1699&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pubmed">32100123</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q, Zhao X, Li S, et al. . CSF neurofilament light chain elevation predicts ALS severity and progression. Front Neurol. 2020;11:919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484044</ArticleId><ArticleId IdType="pubmed">32982935</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridel C, van Wieringen WN, Zetterberg H, et al. . Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and meta-analysis. JAMA Neurol. 2019;76(9):1035&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580449</ArticleId><ArticleId IdType="pubmed">31206160</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">30967444</ArticleId></ArticleIdList></Reference><Reference><Citation>Skillback T, Mattsson N, Blennow K, Zetterberg H. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(5&#x2013;6):397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">28631955</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodovitch A, Boucraut J, Delmont E, et al. . Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS. Sci Rep. 2021;11(1):703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7803734</ArticleId><ArticleId IdType="pubmed">33436881</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL, Bron EE, Poos JM, et al. . A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain. 2021;17:e053497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9166533</ArticleId><ArticleId IdType="pubmed">34633446</ArticleId></ArticleIdList></Reference><Reference><Citation>Behzadi A, Pujol-Calderon F, Tjust AE, et al. . Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics. Sci Rep. 2021;11(1):22128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8585882</ArticleId><ArticleId IdType="pubmed">34764380</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O, Schultz SA, Apel A, et al. . Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019;25(2):277&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Sako W, Murakami N, Izumi Y, Kaji R. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis. J Neurol Sci. 2015;352(1&#x2013;2):84&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">25868897</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards KR, Garten L, Button J, O&#x2019;Connor J, Kamath V, Frazier C. Neurofilament light chain as an indicator of exacerbation prior to clinical symptoms in multiple sclerosis. Mult Scler Relat Disord. 2019;31:59&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">30927733</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Janelidze S, Al Khleifat A, et al. . A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12(1):3400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185001</ArticleId><ArticleId IdType="pubmed">34099648</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijnenburg YA, Janssen JC, Schoonenboom NS, et al. . CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls. Dement Geriatr Cogn Disord. 2007;23(4):225&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">17290105</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan KB, Glass JD, Crook JE, et al. . Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(4):467&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">23117489</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Lombardi V, et al. . Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7&#x2013;8):538&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Remnestal J, Oijerstedt L, Ullgren A, et al. . Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers. Transl Neurodegener. 2020;9(1):27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7310563</ArticleId><ArticleId IdType="pubmed">32576262</ArticleId></ArticleIdList></Reference><Reference><Citation>Haggmark A, Mikus M, Mohsenchian A, et al. . Plasma profiling reveals three proteins associated to amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2014;1(8):544&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4184557</ArticleId><ArticleId IdType="pubmed">25356426</ArticleId></ArticleIdList></Reference><Reference><Citation>Bright F, Werry EL, Dobson-Stone C, et al. . Neuroinflammation in frontotemporal dementia. Nat Rev Neurol. 2019;15(9):540&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">31324897</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137(5):715&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathcke CN, Vestergaard H. YKL-40&#x2013;an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009;8:61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789050</ArticleId><ArticleId IdType="pubmed">19930630</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordenbaek C, Johansen JS, Junker P, Borregaard N, Sorensen O, Price PA. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J Infect Dis. 1999;180(5):1722&#x2013;1726.</Citation><ArticleIdList><ArticleId IdType="pubmed">10515841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CG, Dela Cruz CS, Herzog E, Rosenberg SM, Ahangari F, Elias JA. YKL-40, a chitinase-like protein at the intersection of inflammation and remodeling. Am J Respir Crit Care Med. 2012;185(7):692&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">22467800</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Weydt P, Steinacker P, et al. . Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry. 2019;90:4&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">30224549</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu L, An J, Kovalik T, Gendron T, Petrucelli L, Bowser R. Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes. J Neurol Neurosurg Psychiatry. 2020;91:350&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147184</ArticleId><ArticleId IdType="pubmed">31937582</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres-Benito P, Dominguez R, Colomina MJ, Llorens F, Povedano M, Ferrer I. YKL40 in sporadic amyotrophic lateral sclerosis: Cerebrospinal fluid levels as a prognosis marker of disease progression. Aging. 2018;10(9):2367&#x2013;2382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6188478</ArticleId><ArticleId IdType="pubmed">30215603</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Campo M, Galimberti D, Elias N, et al. . Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. Ann Clin Transl Neurol. 2018;5(10):1163&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6186934</ArticleId><ArticleId IdType="pubmed">30349851</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollacott IOC, Nicholas JM, Heller C, et al. . Cerebrospinal fluid YKL-40 and chitotriosidase levels in frontotemporal dementia vary by clinical, genetic and pathological subtype. Dement Geriatr Cogn Disord. 2020;49(1):56&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7513620</ArticleId><ArticleId IdType="pubmed">32344399</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen CE, Elias N, Koel-Simmelink MJ, et al. . Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimers Dement (Amst). 2016;2:86&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879654</ArticleId><ArticleId IdType="pubmed">27239539</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldacci F, Lista S, Cavedo E, Bonuccelli U, Hampel H. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. Expert Rev Proteomics. 2017;14(4):285&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">28281838</ArticleId></ArticleIdList></Reference><Reference><Citation>Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. 2011;93(3):421&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">21219963</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiki A, Kamada M, Kawamura Y, et al. . Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem. 2016;136(2):258&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">26485083</ArticleId></ArticleIdList></Reference><Reference><Citation>Heller C, Foiani MS, Moore K, et al. . Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020;91(3):263&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">31937580</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A, Ashton NJ, Karikari TK, et al. . Serum glial fibrillary acidic protein (GFAP) is a marker of disease severity in frontotemporal lobar degeneration. J Alzheimers Dis. 2020;77(3):1129&#x2013;1141.</Citation><ArticleIdList><ArticleId IdType="pubmed">32804092</ArticleId></ArticleIdList></Reference><Reference><Citation>Benninger F, Glat MJ, Offen D, Steiner I. Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Clin Neurosci. 2016;26:75&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">26602604</ArticleId></ArticleIdList></Reference><Reference><Citation>Nycander M, Estrada S, Mort JS, Abrahamson M, Bjork I. Two-step mechanism of inhibition of cathepsin B by cystatin C due to displacement of the proteinase occluding loop. FEBS Lett. 1998;422(1):61&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">9475170</ArticleId></ArticleIdList></Reference><Reference><Citation>George PM, Sheat JM. Cystatin C quantification in CSF. Clin Chem. 1989;35(1):179&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">2491975</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai A, Ryu JK, Terashima M, et al. . Neuronal cell death induced by cystatin C in vivo and in cultured human CNS neurons is inhibited with cathepsin B. Brain Res. 2005;1066(1&#x2013;2):120&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">16325785</ArticleId></ArticleIdList></Reference><Reference><Citation>Zi M, Xu Y. Involvement of cystatin C in immunity and apoptosis. Immunol Lett. 2018;196:80&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112947</ArticleId><ArticleId IdType="pubmed">29355583</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto K, Hirai S, Amari M, Watanabe M, Sakurai A. Bunina bodies in amyotrophic lateral sclerosis immunostained with rabbit anti-cystatin C serum. Neurosci Lett. 1993;162(1&#x2013;2):125&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">8121614</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto K, Mizuno Y, Fujita Y. Bunina bodies in amyotrophic lateral sclerosis. Neuropathology. 2008;28(2):109&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">18069968</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S, Williams E, Ganchev P, et al. . Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem. 2005;95(5):1461&#x2013;1471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1540444</ArticleId><ArticleId IdType="pubmed">16313519</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji-Akimoto S, Yabe I, Niino M, Kikuchi S, Sasaki H. Cystatin C in cerebrospinal fluid as a biomarker of ALS. Neurosci Lett. 2009;452(1):52&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">19444952</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y, Zhu W, Cui F, et al. . Measurement of cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Int J Clin Exp Pathol. 2015;8(5):5419&#x2013;5426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4503116</ArticleId><ArticleId IdType="pubmed">26191245</ArticleId></ArticleIdList></Reference><Reference><Citation>Heywood WE, Hallqvist J, Heslegrave AJ, et al. . CSF pro-orexin and amyloid-beta38 expression in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging. 2018;72:171&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6221294</ArticleId><ArticleId IdType="pubmed">30292090</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong XM, Hou L, Luo XN, et al. . Alterations of CSF cystatin C levels and their correlations with CSF Alphabeta40 and Alphabeta42 levels in patients with Alzheimer's disease, dementia with Lewy bodies and the atrophic form of general paresis. PLoS ONE. 2013;8(1):e55328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558470</ArticleId><ArticleId IdType="pubmed">23383156</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, et al. . Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134(Pt 5):1293&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Wang J, et al. . ALS patients&#x2019; regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017;2(5):e89530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Evangelopoulos E, Sereti E, et al. . Alterations of T cell subsets in ALS: A systemic immune activation? Acta Neurol Scand. 2012;125(4):260&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">21651502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Liao B, Henkel JS, Appel SH. Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiol Dis. 2012;48(3):418&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3897268</ArticleId><ArticleId IdType="pubmed">22820142</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannelli I, Heath P, Shaw PJ, Kirby J. The involvement of regulatory T cells in amyotrophic lateral sclerosis and their therapeutic potential. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(5&#x2013;6):435&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">32484719</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano M, Fanelli G, Albany CJ, Giganti G, Lombardi G. Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity. Front Immunol. 2019;10:43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6371029</ArticleId><ArticleId IdType="pubmed">30804926</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Chataway T, Schultz DW, Rush RA, Rogers ML. The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis. PLoS ONE. 2014;9(1):e87398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903651</ArticleId><ArticleId IdType="pubmed">24475283</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia R, Shepheard S, Jin J, et al. . Urinary extracellular domain of neurotrophin receptor p75 as a biomarker for amyotrophic lateral sclerosis in a Chinese cohort. Sci Rep. 2017;7(1):5127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5506052</ArticleId><ArticleId IdType="pubmed">28698670</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi G, Shao S, Zhou J, Huang K, Bi FF. Urinary p75(ECD) levels in patients with amyotrophic lateral sclerosis: A meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2021:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">34726989</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonenko G, Baker E, Stevenson-Hoare J, et al. . Identifying individuals with high risk of Alzheimer's disease using polygenic risk scores. Nat Commun. 2021;12(1):4506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8302739</ArticleId><ArticleId IdType="pubmed">34301930</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagenaars SP, Radakovic R, Crockford C, et al. . Genetic risk for neurodegenerative disorders, and its overlap with cognitive ability and physical function. PLoS ONE. 2018;13(6):e0198187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983413</ArticleId><ArticleId IdType="pubmed">29856801</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp F, Mann M. A primer on concepts and applications of proteomics in neuroscience. Neuron. 2017;96(3):558&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pubmed">29096073</ArticleId></ArticleIdList></Reference><Reference><Citation>Begcevic I, Brinc D, Brown M, et al. . Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach. J Proteomics. 2018;182:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">29684683</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W, Wan X, Liu B, et al. . Specific changes of serum proteins in Parkinson's disease patients. PLoS ONE. 2014;9(4):e95684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000217</ArticleId><ArticleId IdType="pubmed">24769800</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidsson P, Sjogren M, Andreasen N, et al. . Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res Mol Brain Res. 2002;109(1&#x2013;2):128&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">12531522</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruetschi U, Zetterberg H, Podust VN, et al. . Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol. 2005;196(2):273&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">16154129</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL, Meeter LH, Stingl C, et al. . Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. Ann Clin Transl Neurol. 2019;6(4):698&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6469343</ArticleId><ArticleId IdType="pubmed">31019994</ArticleId></ArticleIdList></Reference><Reference><Citation>Barschke P, Oeckl P, Steinacker P, Ludolph A, Otto M. Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis. Expert Rev Proteomics. 2017;14(9):769&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">28799854</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinetti GM, Ungar LH, Lange DJ, et al. . Identification of potential CSF biomarkers in ALS. Neurology. Apr. 2006;66(8):1218&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">16481598</ArticleId></ArticleIdList></Reference><Reference><Citation>von Neuhoff N, Oumeraci T, Wolf T, et al. . Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: Obstacles and perspectives in translating a novel marker panel to the clinic. PLoS ONE. 2012;7(9):e44401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3435306</ArticleId><ArticleId IdType="pubmed">22970211</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryberg H, An J, Darko S, et al. . Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve 2010;42(1):104&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2975276</ArticleId><ArticleId IdType="pubmed">20583124</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins MA, An J, Hood BL, Conrads TP, Bowser RP. Label-free LC-MS/MS proteomic analysis of cerebrospinal fluid identifies protein/pathway alterations and candidate biomarkers for amyotrophic lateral sclerosis. J Proteome Res. 2015;14(11):4486&#x2013;4501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5592736</ArticleId><ArticleId IdType="pubmed">26401960</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Mogel H, Lehmensiek V, et al. . Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS). Neurochem Res. 2008;33(11):2358&#x2013;2363.</Citation><ArticleIdList><ArticleId IdType="pubmed">18481174</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Liu XH, Wu JJ, et al. . Proteomic analysis of cerebrospinal fluid in amyotrophic lateral sclerosis. Exp Ther Med. 2016;11(6):2095&#x2013;2106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4887813</ArticleId><ArticleId IdType="pubmed">27284291</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S, Nicholl GC, Henry S, et al. . Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects. Amyotroph Lateral Scler. 2007;8(6):373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829467</ArticleId><ArticleId IdType="pubmed">17852009</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Lehmensiek V, Mogel H, et al. . Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neurosci Lett. 2010;468(1):23&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">19853641</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Lee A, Nouwens A, Henderson RD, McCombe PA. Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(5&#x2013;6):362&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">29384411</ArticleId></ArticleIdList></Reference><Reference><Citation>Bereman MS, Beri J, Enders JR, Nash T. Machine learning reveals protein signatures in CSF and plasma fluids of clinical value for ALS. Sci Rep. 2018;8(1):16334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6218542</ArticleId><ArticleId IdType="pubmed">30397248</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Weydt P, Thal DR, Weishaupt JH, Ludolph AC, Otto M. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol. 2020;139(1):119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">31701227</ArticleId></ArticleIdList></Reference><Reference><Citation>Barschke P, Ockl P, Steinacker P, et al. . Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. J Neurol Neurosurg Psychiatry. 2020;91:503&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">32132225</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzeff JS, Bright F, Lo K, et al. . Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. Sci Rep. 2020;10(1):13741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7426269</ArticleId><ArticleId IdType="pubmed">32792518</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WS, Jary E, Pickford R, et al. . Lipidomics analysis of behavioral variant frontotemporal dementia: A scope for biomarker development. Front Neurol. 2018;9:104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5835505</ArticleId><ArticleId IdType="pubmed">29541056</ArticleId></ArticleIdList></Reference><Reference><Citation>Sol J, Jove M, Povedano M, et al. . Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression. Brain Commun. 2021;3(3):fcab143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8361390</ArticleId><ArticleId IdType="pubmed">34396104</ArticleId></ArticleIdList></Reference><Reference><Citation>FernAndez-Eulate G, Ruiz-Sanz JI, Riancho J, et al. . A comprehensive serum lipidome profiling of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(3&#x2013;4):252&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">32106710</ArticleId></ArticleIdList></Reference><Reference><Citation>Murley AG, Jones PS, Coyle Gilchrist I, et al. . Metabolomic changes associated with frontotemporal lobar degeneration syndromes. J Neurol. 2020;267(8):2228&#x2013;2238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359154</ArticleId><ArticleId IdType="pubmed">32277260</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos ALM, Vit&#xf3;rio JG, de Paiva MJN, et al. . Frontotemporal dementia: Plasma metabolomic signature using gas chromatography-mass spectrometry. J Pharm Biomed Anal. 2020;189:113424.</Citation><ArticleIdList><ArticleId IdType="pubmed">32619729</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia R, Chen Q, Zhou Q, et al. . Characteristics of serum metabolites in sporadic amyotrophic lateral sclerosis patients based on gas chromatography-mass spectrometry. Sci Rep. 2021;11(1):20786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8531355</ArticleId><ArticleId IdType="pubmed">34675267</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>